Protalix Biotherapeutics Inc. buy klostergang
Start price
08.04.15
/
50%
€18.27
Target price
08.10.15
€24.00
Performance (%)
-46.14%
End price
08.10.15
€9.84
Summary
This prediction ended on 08.10.15 with a price of €9.84. Massive losses of -46.14% were the result for the BUY prediction by klostergang. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Protalix Biotherapeutics Inc. | 7.912% | 7.912% | 64.344% | -0.841% |
| iShares Core DAX® | -1,36 % | -2,33 % | 3,44 % | 53,51 % |
| iShares Nasdaq 100 | -3,70 % | -1,24 % | 33,08 % | 90,97 % |
| iShares Nikkei 225® | -2,51 % | 6,91 % | 60,78 % | 81,10 % |
| iShares S&P 500 | -1,66 % | -0,64 % | 23,47 % | 67,07 % |
Comments by klostergang for this prediction
In the thread Protalix Biotherapeutics Inc. diskutieren
Protalix BioTherapeutics
Protalex recently received FDA clearance to begin a Phase 1/2 study with PRTX-100 in Immune Thrombocytopenia (ITP).
Previous data with PRTX-100 in patients with Rheumatoid Arthritis (RA) demonstrated the drug to be both safe and highly efficacious.
(Laufzeit überschritten)